Substrate- and species-dependent inhibition of p-glycoprotein-mediated transport: Implications for predicting in vivo drug interactions

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3055-3061

  Zolnerciks, Joseph K ^a,c   Booth Genthe, Catherine L ^b,d   Gupta, Anshul ^b   Harris, Jennifer ^b   Unadkat, Jashvant D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ASTRAZENECA   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Drug interactions; Flow cytometry; In vitro models; P glycoprotein; Species dependent; Substrate dependent

Indexed keywords

4,4 DIFLUORO 5,7 DIMETHYL 4 BORA 3A,4A DIAZAINDACENE; ATAZANAVIR; CYCLOSPORIN A; ELACRIDAR; FLUORESCENT DYE; GLYCOPROTEIN P; ITRACONAZOLE; KETOCONAZOLE; NELFINAVIR; PRAZOSIN; QUINIDINE; QUININE; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; VERAPAMIL;

ACCURACY; ANIMAL CELL; ARTICLE; BIOLOGICAL MODEL; CELL STRAIN; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG TRANSPORT; FLOW CYTOMETRY; IC 50; IN VIVO STUDY; INTESTINE ABSORPTION; NONHUMAN; PREDICTION; SPECIES DIFFERENCE; TRANSPORT KINETICS;

EID: 79958829984     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22566     Document Type: Article

References (24)

1. Keogh JP, Kunta JR. 2006. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27(5):543-554.
2. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. 1989. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86(2):695-698.
3. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. 1987. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84(21):7735-7738.
4. Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S. 1988. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48(7):1926-1929.
5. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD. 2005. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 77(6):503-514.
6. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD. 2009. Imaging the function of P-glycoprotein with radiotracers: Pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86(4):368-377.
7. Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, Unadkat JD. 2006. Verapamil P-glycoprotein transport across the rat blood-brain barrier: Cyclosporine, a concentration inhibition analysis, and comparison with human data. J Pharmacol Exp Ther 317(2):704-710.
8. Hsiao P, Bui T, Ho RJ, Unadkat JD 2008. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos 36(3):481-484.
9. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96(4):1698-1705.
10. Booth-Genthe CL, Louie SW, Carlini EJ, Li B, Leake BF, Eisenhandler R, Hochman JH, Mei Q, Kim RB, Rushmore TH, Yamazaki M. 2006. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): Comparison of rat P-glycoprotein transport to human and mouse. J Pharmacol Toxicol Methods 54(1):78-89.
11. Zolnerciks JK, Wooding C, Linton KJ. 2007. Evidence for a Sav1866-like architecture for the human multidrug transporter P-glycoprotein. FASEB J 21(14):3937-3948.
12. Rais R, Gonzalez PM, Zheng X, Wring SA, Polli JE. 2008. Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J 10(4):596-605.
13. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299(2):620-628.
14. Mihaly GW, Ching MS, Klejn MB, Paull J, Smallwood RA. 1987. Differences in the binding of quinine and quinidine to plasma proteins. Br J Clin Pharmacol 24(6):769-774.
15. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL. 2000. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28(12):1440-1448.
16. Martin C, Berridge G, Higgins CF, Callaghan R. 1997. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction. Br J Pharmacol 122(4):765-771.
17. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. 2000. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58(3):624-632.
18. Loo TW, Bartlett MC, Clarke DM. 2003. Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein. J Biol Chem 278(41):39706-39710.
19. Lugo MR, Sharom FJ. 2005. Interaction of LDS-751 and rhodamine 123 with P-glycoprotein: Evidence for simultaneous binding of both drugs. Biochemistry 44(42):14020-14029.
20. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. 2009. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323(5922):1718-1722.
21. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
22. Akiyama S, Cornwell MM, Kuwano M, Pastan I, Gottesman MM. 1988. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 33(2):144-147.
23. Pires MM, Emmert D, Hrycyna CA, Chmielewski J. 2009. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol 75(1):92-100.
24. Eyal S, Ke B, Muzi M, Link JM, Mankoff DA, Collier AC, Unadkat JD. 2010. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography. Clin Pharmacol Ther 87(5):579-585.